These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6714438)

  • 1. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans.
    Spielberg SP
    Fed Proc; 1984 May; 43(8):2308-13. PubMed ID: 6714438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrofurantoin cytotoxicity. In vitro assessment of risk based on glutathione metabolism.
    Spielberg SP; Gordon GB
    J Clin Invest; 1981 Jan; 67(1):37-41. PubMed ID: 7451657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetaminophen toxicity in human lymphocytes in vitro.
    Spielberg SP
    J Pharmacol Exp Ther; 1980 May; 213(2):395-8. PubMed ID: 7365697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione synthetase-deficient lymphocytes and acetaminophen toxicity.
    Spielberg SP; Gordon GB
    Clin Pharmacol Ther; 1981 Jan; 29(1):51-5. PubMed ID: 7460474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticonvulsant toxicity in vitro: possible role of arene oxides.
    Spielberg SP; Gordon GB; Blake DA; Mellits ED; Bross DS
    J Pharmacol Exp Ther; 1981 May; 217(2):386-9. PubMed ID: 7229980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions.
    Petersen KU
    Arzneimittelforschung; 2002; 52(6):423-9. PubMed ID: 12109041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro lymphocyte toxicity to a phenytoin metabolite in phenytoin induced cutaneous adverse drug eruptions.
    Dwivedi R; Gogtay N; Kharkar V; Amladi S; Kshirsagar N
    Indian J Dermatol Venereol Leprol; 2004; 70(4):217-20. PubMed ID: 17642618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor.
    Ganey PE; Luyendyk JP; Maddox JF; Roth RA
    Chem Biol Interact; 2004 Nov; 150(1):35-51. PubMed ID: 15522260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and the concept of individualized medicine.
    Shastry BS
    Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants.
    Wolkenstein P; Charue D; Laurent P; Revuz J; Roujeau JC; Bagot M
    Arch Dermatol; 1995 May; 131(5):544-51. PubMed ID: 7741540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predisposition to phenytoin hepatotoxicity assessed in vitro.
    Spielberg SP; Gordon GB; Blake DA; Goldstein DA; Herlong HF
    N Engl J Med; 1981 Sep; 305(13):722-7. PubMed ID: 6790991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility.
    Kearns GL; Wheeler JG; Childress SH; Letzig LG
    J Pediatr; 1994 Nov; 125(5 Pt 1):805-11. PubMed ID: 7965438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity.
    Lavergne SN; Park BK; Naisbitt DJ
    Curr Opin Allergy Clin Immunol; 2008 Aug; 8(4):299-307. PubMed ID: 18596585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug metabolite toxicity assessed in human lymphocytes with a purified, reconstituted cytochrome P-450 system.
    Leeder JS; Cannon M; Nakhooda A; Spielberg SP
    J Pharmacol Exp Ther; 1988 Jun; 245(3):956-62. PubMed ID: 3385648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetically hazardous drugs: a proposed new scoring method.
    Szórády I; Sánta A
    Acta Physiol Hung; 1991; 77(3-4):305-18. PubMed ID: 1755332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic approaches to the prediction of drug response.
    Vesell ES
    NIDA Res Monogr; 1986; 66():25-40. PubMed ID: 3106816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.